Source-grounded facts extracted from Bolt Biotherapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Bolt Biotherapeutics, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026 at the 2026-06-10 meeting.
“The selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was ratified.”
Bolt Biotherapeutics, Inc. shareholders approved Election of Class II directors at the 2026-06-10 meeting.
“The following director nominees were elected to serve as Class II members of the Company’s board of directors until the Company’s 2029 Annual Meeting of Stockholders, or until their respective successor is duly elected and qualified, or until their respective death, resignation or removal:”
Bolt Biotherapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue Total collaboration revenue was $26,000 for the quarter ended March 31, 2026.
“Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update”
Bolt Biotherapeutics, Inc. reported the full year ended December 31, 2025 results: revenue $7.7 million.
“Total collaboration revenue was $2.5 million and $7.7 million for the fourth quarter and full year ended December 31, 2025, respectively”
Bolt Biotherapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $2.5 million.
“Total collaboration revenue was $2.5 million and $7.7 million for the fourth quarter and full year ended December 31, 2025, respectively”
Bolt Biotherapeutics, Inc. announced a restructuring with charges of between approximately $1.5 million to $2.0 million affecting the Company (approximately 20 employees, or approximately 50% of the Company’s workforce).
“On October 1, 2025, Bolt Biotherapeutics, Inc., a Delaware corporation (the “Company”), implemented a restructuring plan pursuant to which it will reduce overall operating expenses to preserve cash. The restructuring plan includes a reduction of the Company’s current workforce by approximately 20 employees, or approximately 50% of the Company’s workforce. The Company estimates that it will incur aggregate pre-tax charges between approximately $1.5 million to $2.0 million in connection with the reduction-in-force, primarily consisting of severance payments, employee benefits, and related costs.”
Bolt Biotherapeutics, Inc.: Filed a Certificate of Amendment to effect a one-for-twenty reverse stock split of common stock (effective 2025-06-06).
“On June 6, 2025, Bolt Biotherapeutics, Inc., a Delaware corporation (the “Company”), filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Certificate of Incorporation (the “Amendment”), to effect a one-for-twenty (1:20) reverse stock split of its outstanding common stock, effective as of June 6, 2025 (the “Reverse Stock Split”).”
Bolt Biotherapeutics, Inc.: Reduced quorum requirement for stockholder meetings from a majority to one-third of outstanding shares (effective 2025-04-15).
“On April 15, 2025, the board of directors of Bolt Biotherapeutics, Inc. (the “Company”) amended and restated the Company’s amended and restated bylaws (as amended and restated, the “Amended and Restated Bylaws”), effective immediately.”
Bolt Biotherapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“January 2, 2025, the Company received written notice from Nasdaq notifying the Company that its application to transfer the listing of its common stock to The Nasdaq Capital Market was approved. The approval is based upo”
Jakob Dupont was appointed as Class II member of the Board at Bolt Biotherapeutics, Inc..
“Effective September 3, 2024, the Board appointed Jakob Dupont, M.D., Ph.D., to serve as a Class II member of the Board.”
Frank D. Lee resigned as member of the Board at Bolt Biotherapeutics, Inc..
“On September 1, 2024, Frank D. Lee notified the Company of his resignation as a member of the Board and the committees thereof, effective as of September 3, 2024.”
James Healy resigned as member of the Board at Bolt Biotherapeutics, Inc..
“On August 28, 2024, James Healy, M.D., Ph.D., notified Bolt Biotherapeutics, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and the committees thereof, effective as of September 3, 2024.”
Bolt Biotherapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 14, 2024, Bolt Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024 and a corporate update.”
Bolt Biotherapeutics, Inc. announced a restructuring with charges of $3.0 million to $4.0 million affecting Bolt Biotherapeutics (approximately 50 employees, or approximately 50% of the Company's workforce).
“On May 14, 2024, the Company announced a strategic pipeline prioritization and restructuring plan pursuant to which it will discontinue developing trastuzumab imbotolimod, formerly known as BDC-1001, in order to focus on the Company’s next generation ISAC platform including new clinical candidate, BDC-4182, targeting Claudin 18.2, and Phase 1 asset, BDC-3042, a Dectin-2 agonist antibody, and reduce overall operating expenses to preserve cash. The restructuring plan includes a reduction of the Company’s current workforce by approximately 50 employees, or approximately 50% of the Company’s workforce. The Company estimates that it will incur aggregate pre-tax charges between approximately $3.0 million to $4.0 million in connection with the reduction-in-force, primarily consisting of severance payments, employee benefits, and related costs.”
Edith A. Perez departed as Chief Medical Officer at Bolt Biotherapeutics, Inc..
“Edith A. Perez, M.D. is stepping down as the Company’s Chief Medical Officer of the Company, effective as of May 15, 2024.”
Randall C. Schatzman resigned as Member of the Board of Directors at Bolt Biotherapeutics, Inc..
“Randall C. Schatzman, Ph.D. is stepping down as the Company’s Chief Executive Officer and has resigned as a member of the Board, both effective as of May 15, 2024.”
Randall C. Schatzman departed as Chief Executive Officer at Bolt Biotherapeutics, Inc..
“Randall C. Schatzman, Ph.D. is stepping down as the Company’s Chief Executive Officer and has resigned as a member of the Board, both effective as of May 15, 2024.”
Edgar G. Engleman resigned as Member of the Board of Directors at Bolt Biotherapeutics, Inc..
“On May 13, 2024, Edgar G. Engleman, M.D. notified the Company of his resignation as a member of the Company's Board of Directors (the “Board”) and from all committees of the Board on which he served, effective as of May 15, 2024.”
Bolt Biotherapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
“On March 21, 2024, Bolt Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023.”
Bolt Biotherapeutics, Inc. reported the third quarter ended September 30, 2023 results: revenue $2.5 million.
“2023. Cash on hand is expected to fund multiple milestones and operations through 2025. Third Quarter 2023 Financial Results • Collaboration Revenue – Collaboration revenue was $2.5 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter in 2022. Revenue in the comparative periods were generated from the services performed”
Bolt Biotherapeutics, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2023-06-12 meeting.
“The selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. Votes For Votes Against Votes Abstaining 26,831,426 33,439 15,578”
Bolt Biotherapeutics, Inc. shareholders approved Election of Class II directors at the 2023-06-12 meeting.
“The following director nominees were elected to serve as Class II members of the Company’s board of directors until the Company’s 2026 Annual Meeting of Stockholders, or until their respective successor is duly elected and qualified, or until their respective death, resignation or removal: Nominee Votes For Votes Withheld Broker Non-Votes Randall C. Schatzman, Ph.D. 18,339,155 49,830 8,491,458 Edgar G. Engleman, M.D. 18,300,413 88,572 8,491,458 James I. Healy, M.D., Ph.D. 14,449,941 3,939,044 8,491,458”
Bolt Biotherapeutics, Inc. reported financial results for first quarter ended March 31, 2023.
“Bolt Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.”
Bolt Biotherapeutics, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue Collaboration Revenue – Collaboration revenue was $1.4 million for the quarter and $5.7 million for the full year ended.
“– 5:00 p.m. EDT Location: Orange County Convention Center, Section 24 Fourth Quarter and Full Year 2022 Financial Results • Collaboration Revenue – Collaboration revenue was $1.4 million for the quarter and $5.7 million for the full year ended December 31, 2022, compared to $0.5 million and $1.3 million for the same quarter and year in 2021. The collaboration”
Laura Berner was appointed as Class I Director at Bolt Biotherapeutics, Inc..
“the Board then appointed Laura Berner to the Board as a Class I director of the Company, effective immediately”
Bolt Biotherapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $2.1 million.
“16th, 2022, with a corporate presentation at 1:15 p.m. ET in New York, New York. Third Quarter 2022 Financial Results • Collaboration Revenue – Collaboration revenue was $2.1 million for the third quarter ended September 30, 2022, compared to $0.8 million for the same quarter in 2021. This represents 50% growth over the second quarter of 2022 as Bolt”
David Dornan resigned as Chief Scientific Officer at Bolt Biotherapeutics, Inc..
“On March 1, 2022, David Dornan, Ph.D. notified Bolt Biotherapeutics, Inc. of his resignation as our Chief Scientific Officer, effective March 11, 2022.”
Nicole Onetto was appointed as Director at Bolt Biotherapeutics, Inc..
“On December 14, 2021, upon recommendation of the Nominating and Corporate Governance Committee, the Board appointed Nicole Onetto to the Board as a Class III director of the Company, effective immediately, to fill the vacancy on the Board.”
Ashish Khanna resigned as Director at Bolt Biotherapeutics, Inc..
“On December 13, 2021, Ashish Khanna, a director of Bolt Biotherapeutics, Inc. (the “Company”) resigned as a member of the Company’s Board of Directors (the “Board”), effective immediately.”
Jim Healy was appointed as Lead Independent Director at Bolt Biotherapeutics, Inc..
“the Board appointed Jim Healy, an existing member of the Board, to serve as the lead independent director of the Company”
Frank Lee was appointed as Director at Bolt Biotherapeutics, Inc..
“The Board then appointed Brian O’Callaghan and Frank Lee to the Board as Class I directors of the Company, effective immediately”
Brian O'Callaghan was appointed as Director at Bolt Biotherapeutics, Inc..
“The Board then appointed Brian O’Callaghan and Frank Lee to the Board as Class I directors of the Company, effective immediately”
Peter Moldt resigned as Director at Bolt Biotherapeutics, Inc..
“On November 15, 2021, Peter Moldt, a director of Bolt Biotherapeutics, Inc. (the “Company”) resigned as a member of the Company’s Board of Directors (the “Board”), effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.